For A strategic Analysis of Regulatory Cannabis Policies (ASTRACAN)
Driven and coordinated by the OFDT thanks to funding from the 2019 Fund for Combatting Addiction to psychoactive substances for 3 years (2019-2021), the ASTRACAN project aims to compare the regulatory policies of non-medical cannabis use implemented in the United States (where 15 states have opened a legal cannabis market despite the federal ban) and Canada.
This collective comparative research, coordinated by the OFDT in partnership with two university research laboratories in political science (Université Paris 1 Panthéon-Sorbonne and Université de Québec à Montréal), is particularly interested in the conditions for the implementation of these reforms and to their first observable effects in terms of public health, through 6 case studies in the United States (Washington State, Oregon, California) and Canada (British Columbia, Ontario, Quebec).
This research is a follow-up to a first study carried out between 2015 and 2017 in Colorado, Washington State and Uruguay (Cannalex), which mapped the relevant stakeholders and reviewed the issues raised in the early years of the legalisation of cannabis for recreational use.
The field study is targeting 6 North American jurisdictions that legalised recreational cannabis between 2012 and 2018, corresponding to:
- the 3 waves of legalisation in the United States (Washington State in 2012, Oregon in 2014, California in 2016) and the different sized markets (California being one of the biggest user markets in the world);
- the 3 most populous provinces in Canada, which have implemented rather restrictive regulatory models (public-private system in British Columbia, private system in Ontario and public system in Quebec).
This section aims to bring together all the work carried out within the framework of the ASTRACAN project, namely:
1. Three reviews of scientific evidence produced on behalf of the OFDT on the experiences of cannabis legalisation for medical and non-medical use carried out in the United States and Canada:
a. The legalization of cannabis in Canada. Case studies: British Columbia, Ontario, Quebec
(author: Gabriel Lévesque) - October 2020
b. Effects of medical and non-medical marijuana legalization on public health in the United States
(author: Adam Darnell, DDR Consulting) - November 2020
c. Marijuana Legalization in the United States: A Comparison of Non-Medical Marijuana Policies and Regulations across Ten U.S. States
(author: Gillian Schauer, Gillian Schauer Consulting) - November 2020
2. A summary in the form of a review of the first global legalisation experiments carried out in the United States, Canada and Uruguay (2014-2020) (in the Théma collection, to be published in the first half of 2021, author: Ivana Obradovic, OFDT).
3. The results of field studies scheduled for the first half of 2021 (around sixty interviews with three types of regulatory actors and direct observations on site):
a. summary of the United States field study (authors: Ivana Obradovic and Anne-France Taiclet)
b. summary of the Canada field study (authors: Ivana Obradovic and Maude Benoit)
c. comparative summary (authors: Ivana Obradovic, Maude Benoit and Anne-France Taiclet)
Drugs in Europe
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.